Regina received a PhD in Cardiovascular Physiology/Pharmacology at the University of Göteborg in 1993. She then continued in academia for eight years. During this time she worked at the University of Göteborg, University of Ottawa, University of Queensland and University of Nevada. In 1997 she became Associate Professor at the University of Göteborg. Regina has a broad scientific background in human and animal physiology, particularly in cardiovascular physiology. She has published over 40 papers and review articles within the field. She has detailed knowledge in the area of atherosclerosis and cardiovascular physiology – including human disease pathophysiological mechanisms, medical need, current treatment and related pre-clinical science and capabilities. During her fourteen years at AstraZeneca, Regina has worked in drug projects and been in project leader roles for drug projects from lead optimisation to clinical phases in addition to her line responsibilities. In January 2011, Regina was appointed Senior Project Director and is now leading the Cardiac Regeneration Strategy Area focusing on heart failure and the VEGF-A modRNA project in CVMD iMed. In 2014, Regina was also appointed Head of Bioscience Department Heart Failure Department with overall accountability to initiate and progress the portfolio in the CV and heart failure area.

Pharmaceuticals